Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact email@example.com
SOURCE Research and Markets
DUBLIN, March 5, 2018 /PRNewswire/ --
The "Global Respiratory Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
Global Respiratory Partnering 2012 to 2018 provides the full collection of Respiratory disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals.
The report presents financial deal terms values for Respiratory deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
In addition, a comprehensive appendix is provided with each report of all Respiratory partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Respiratory partnering and dealmaking since 2012.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Respiratory technologies and products.
Global Respiratory Partnering 2012 to 2018 includes:
In Global Respiratory Partnering 2012 to 2018, available deals and contracts are listed by:
Analyzing actual contract agreements allows assessment of the following:
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Respiratory dealmaking
2.2. Respiratory partnering over the years
2.3. Respiratory partnering by deal type
2.4. Respiratory partnering by industry sector
2.5. Respiratory partnering by stage of development
2.6. Respiratory partnering by technology type
2.7. Respiratory partnering by therapeutic indication
Chapter 3 - Financial deal terms for Respiratory partnering
3.2. Disclosed financials terms for Respiratory partnering
3.3. Respiratory partnering headline values
3.4. Respiratory deal upfront payments
3.5. Respiratory deal milestone payments
3.6. Respiratory royalty rates
Chapter 4 - Leading Respiratory deals and dealmakers
4.2. Most active in Respiratory partnering
4.3. List of most active dealmakers in Respiratory
4.4. Top Respiratory deals by value
Chapter 5 - Respiratory contract document directory
5.2. Respiratory partnering deals where contract document available
Chapter 6 - Respiratory dealmaking by therapeutic target
6.2. Deals by Respiratory therapeutic target
For more information about this report visit https://www.researchandmarkets.com/research/8rvmq3/global?w=5
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-respiratory-partnering-analysis-report-2012-2018-full-collection-of-deals-signed-between-the-worlds-pharma-and-biotech-companies-since-2012-300608193.html
©2017 PR Newswire. All Rights Reserved.